Baudax Bio
(OTC) BXRXQ
Baudax Bio Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$310.00K
Net Income (TTM)
$7.16M
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
-544.19 (Low)
Dividend
$0.00
Beta (Volatility)
-544.19 (Low)
Price
$0.00
Volume
800
Open
$0.00
Price
$0.00
Volume
800
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.00
Dividend
$0.00
Beta (Volatility)
-544.19 (Low)
Price
$0.00
Volume
800
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.00
BXRXQ News
BXRXQ: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Baudax Bio
Industry
Pharmaceuticals
Sector
Health CareEmployees
9
CEO
Gerri Henwood
Website
www.baudaxbio.comHeadquarters
Malvern, PA 19355, US
BXRXQ Financials
Key Financial Metrics (TTM)
Gross Margin
-5%
Operating Margin
-45%
Net Income Margin
-46%
Return on Equity
0%
Return on Capital
5%
Return on Assets
-6%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$0.00
Shares Outstanding
43.59M
Volume
800
Short Interest
0.00%
Avg. Volume
1.08K
Financials (TTM)
Gross Profit
$5.74M
Operating Income
$56.81M
EBITDA
$33.58M
Operating Cash Flow
$27.79M
Capital Expenditure
$20.00K
Free Cash Flow
$27.81M
Cash & ST Invst.
$5.26M
Total Debt
$7.12M
Baudax Bio Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
+100.0%
Gross Margin
0.00%
N/A
Market Cap
$0.00
N/A
Market Cap/Employee
N/A
N/A
Employees
9
N/A
Net Income
$1.93M
+93.4%
EBITDA
$5.41M
+80.7%
Quarterly Fundamentals
Net Cash
$7.73M
-217.1%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
-100.0%
Long Term Debt
$2.53M
+16.2%
Short Term Debt
$5.57M
-5.8%
Return on Assets
-5.86%
N/A
Return on Invested Capital
4.97%
N/A
Free Cash Flow
$2.43M
+37.4%
Operating Cash Flow
$2.41M
+37.9%